P0627
PTH-glycine
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H8N2OS
CAS Number:
Molecular Weight:
192.24
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
217-927-3
MDL number:
storage temp.
−20°C
SMILES string
O=C1CNC(=S)N1c2ccccc2
InChI
1S/C9H8N2OS/c12-8-6-10-9(13)11(8)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)
InChI key
ZZRIQDWDJVLELF-UHFFFAOYSA-N
Gene Information
human ... CNR1(1268), CNR2(1269)
rat ... Faah(29347)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
[The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].
Takeo Kosaka et al.
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 353-359 (2013-03-22)
Enzalutamide (Xtandi) for prostate cancer.
The Medical letter on drugs and therapeutics, 55(1411), e20-e20 (2013-03-08)
Sumanta K Pal et al.
Expert opinion on pharmacotherapy, 14(5), 679-685 (2013-02-28)
The FDA approval of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) in 2005 marked a major milestone, as it was the first approved agent for this disease that demonstrated a survival advantage in Phase III assessment of this disease. Since
Y S Ha et al.
Drugs of today (Barcelona, Spain : 1998), 49(1), 7-13 (2013-01-31)
Castration-resistant prostate cancer (CRPC) remains a major clinical challenge, given the mechanistic heterogeneity due to a complex signal transduction network. Enzalutamide (MDV-3100), recently approved by the U.S. Food and Drug Administration (FDA) at a dose of 160 mg/day for the
Manoj P Menon et al.
Current oncology reports, 15(2), 69-75 (2013-01-24)
Enzalutamide, formerly known as MDV3100, is an oral second generation androgen receptor (AR) inhibitor that was chosen from a screen of agents and shown in preclinical studies to have greater affinity for the AR than its predecessors without any agonistic
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service